Last Updated: November 16, 2026

Litigation Details for Warner Chilcott Company, LLC v. Lupin Ltd. (Fed. Cir. 2014)

« Back to Dashboard


Small Molecule Drugs cited in Warner Chilcott Company, LLC v. Lupin Ltd.
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Last updated: July 27, 2026

ecutive summary
Warner Chilcott Company, LLC v. Lupin Ltd., No. 14-1262 (Fed. Cir.), concerns patent infringement and post-grant related issues tied to Warner Chilcott’s product portfolio and Lupin’s proposed generic entry. The case number indicates appellate posture in the Federal Circuit, but the record details needed to produce a complete litigation summary (district court caption, patents asserted, procedural history, claim construction outcomes, and the final Federal Circuit disposition) are not provided here.

Warner Chilcott Company, LLC v. Lupin Ltd. |14-1262: What patents were at issue and how did the Federal Circuit rule?

What is the procedural posture of Warner Chilcott v. Lupin Ltd. 14-1262 (Fed. Cir.)?

A “14-1262” Federal Circuit docket number signals an appeal from a lower tribunal decision. A complete litigation summary requires: the district court case number and caption, the patents-in-suit, the asserted claims, and the Federal Circuit judgment (affirmed, reversed, vacated, remanded) with dates and the panel. Those elements are not included in the input.

What courts were involved?

  • Lower court: not specified in the provided information.
  • Appellate court: Federal Circuit implied by “|14-1262” format, but not explicitly confirmed.

What relief was sought?

  • In an infringement appeal, relief usually includes injunction or damages, plus judgment on invalidity/unenforceability defenses. The specific pleadings and outcomes are not provided.

Which Warner Chilcott patents protected the product(s) challenged by Lupin?

Patent-level analysis requires the patent numbers and their assignees. The docket number alone does not identify:

  • the patent family (active ingredient vs. formulation vs. method-of-use)
  • the claim set that survived summary judgment or was decided post-trial
  • whether the patents were Orange Book-listed for a specific NDA/NDA supplement at the time of Lupin’s filing

No patent identifiers are included.

How were claims construed and applied?

Claim construction outcomes drive infringement and validity conclusions. A litigation summary typically reports:

  • constructions of key terms
  • findings on literal infringement vs. equivalents
  • anticipation/obviousness thresholds None of those inputs are available.

What did Lupin challenge in Warner Chilcott’s patent estate in 14-1262?

Generic defendants usually contest infringement and argue invalidity defenses such as:

  • anticipation (35 USC §102)
  • obviousness (35 USC §103)
  • lack of written description/enablement (35 USC §112)
  • prosecution history estoppel or inequitable conduct
    But the specific defenses asserted in this appeal, and which were accepted, are not provided.

Were invalidity theories dispositive at appeal?

A credible analysis requires the Federal Circuit’s reasoning. Without the judgment text or holdings, this cannot be constructed without risk of error.

When did Lupin’s generic entry and FDA pathway relate to this litigation?

An investor-grade linkage ties the appeal to:

  • FDA filing type (ANDA, 505(b)(2))
  • Orange Book patent listings
  • Paragraph IV notice timing
  • any settlement triggering 30-month stay or market-entry dates
    The FDA/Orange Book specifics are not included, so a regulatory timing analysis cannot be produced.

Key litigation “what happened” analysis for dossier use

What is the final outcome in Fed. Cir. docket 14-1262?

Outcome details are not provided. A litigation summary should state:

  • the disposition (affirm/reverse/vacate/remand)
  • whether the case ended on infringement, invalidity, or procedural grounds
  • whether any injunction or permanent injunction was granted or dissolved None of that information is present.

How strong is Warner Chilcott’s position on the asserted claims?

Strength assessment depends on:

  • surviving claim scope after claim construction
  • invalidity findings
  • standards applied under Markman, de novo claim construction, and substantial evidence/clear error
    No claim-level results are available.

How does the 14-1262 result affect generic entry risk for Lupin and other filers?

Market impact depends on:

  • remaining enforceable patents after the decision
  • whether other family members were found invalid
  • settlement terms or covenants not to sue
    Those items are not included.

Timeline (litigation procedural milestones)

No dates are provided in the prompt. Without docket disposition dates, lower court judgment date, briefing milestones, oral argument date, and mandate issue date, a factual timeline cannot be generated.

Table: Docket facts needed for a litigation summary

Field Required for analysis Provided here
District court caption and case number Identifies the trial-level record No
Patents-in-suit Enables claim-by-claim review No
Parties to the appeal (full list) Confirms real parties and alignment No
Federal Circuit disposition Determines market and infringement consequence No
Claim construction and holdings Drives validity/infringement assessment No
Settlement terms / licensing covenants Determines entry timing No
FDA/Orange Book link Connects to 30-month stay and launch No

Key Takeaways

  • The docket number alone is insufficient to generate an accurate, citation-grade litigation summary or outcome analysis for Warner Chilcott Company, LLC v. Lupin Ltd., 14-1262.
  • A correct patent and exclusivity impact analysis must include the patents-in-suit and the Federal Circuit judgment text, none of which are provided.

FAQs

  1. Which specific Warner Chilcott patents were asserted in Fed. Cir. 14-1262?
  2. Did the Federal Circuit affirm a finding of infringement, invalidate the patents, or remand for further proceedings?
  3. What was the effect of the 14-1262 decision on any Orange Book listed patents tied to Lupin’s ANDA?
  4. Were Paragraph IV arguments or noninfringement defenses central to the appeal?
  5. Did the parties reach a settlement or covenant not to sue tied to this docket?

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.